Raloxifene use in clinical practice: Efficacy and safety

Menopause

Volumn 16, Issue 2, 2009, Pages 413-421

  Goldstein, Steven R ^a   Duvernoy, Claire S ^b,c   Calaf, Joaquim ^d   Adachi, Jonathan D ^e   Mershon, John L ^f   Dowsett, Sherie A ^f   Agnusdei, Donato ^f   Stuenkel, Cynthia A ^g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e MCMASTER UNIVERSITY   (Canada)

^f ELI LILLY AND COMPANY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fracture; Invasive breast cancer; Osteoporosis; Raloxifene; Safety

Indexed keywords

ESTROGEN; GESTAGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RALOXIFENE;

ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CANCER INVASION; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LEG CRAMP; LUNG EMBOLISM; OSTEOPOROSIS; PERIPHERAL EDEMA; POSTMENOPAUSE; RISK REDUCTION; STROKE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 67649331971     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181883dae     Document Type: Article

References (51)

1. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with ralox-ifene: results from a 3-year randomized clinical trial. JAMA 1999;282: 637-645.
2. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteopo-rotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761.
3. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
4. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 2001;93: 334-335.
5. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006; 12:5242-5247.
6. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137.
7. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006;295:2727-2741.
8. Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-134.
9. Gloeckler Ries LA, Eisner MP. Cancer of the Female Breast. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, SEER Program, National Institutes of Health, 2008.
10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
11. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-814.
12. National Cancer Institute. Breast cancer risk assessment tool. 2008. Available at: http://www.cancer.gov/bcrisktool/. Accessed March 27, 2008.
13. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337: 1641-1647.
14. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160: 3444-3450.
15. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10:337-344.
16. Siris E, Harris S, Eastell R, et al. Effects of raloxifene on the risk of nonvertebral fractures after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2004;19:S96.
17. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-349.
18. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 1992;7:1389-1398.
19. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617.
20. Qu Y, Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin 2005;21: 1955-1959.
21. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162: 1140-1143.
22. Ensrud KE, Stock JL, Barrett-Connor E, et al. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res 2008;23:112-120.
23. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-489.
24. Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003;33:293-300.
25. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-1112.
26. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348: 1535-1541.
27. WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/ FRAX/. Accessed March 27, 2008.
28. Clinician's guide to prevention and treatment of osteoporosis. 2008. Available at: http://www.nof.org/professionals/Clinicians-Guide.htm. Accessed March 27, 2008.
29. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) study group. JAMA 1999;282:1344-1352.
30. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11:83-91.
31. Martino S, Disch D, Dowsett SA, Keech CA, Mershon J. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-1452.
32. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol 2004;104:837-844.
33. Eli Lilly and Company. Full prescribing information for Evista. 2007. Available at: http://pi.lilly.com/us/evista-pi.pdf. Accessed March 27, 2008.
34. Azevedo GD, Franco RF, Baggio MS, Maranhao TM, Ferriani RA, Silva de Sa MF. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women. Climacteric 2003;6:140-145.
35. Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 2005; 116: 1-13.
36. Sgarabotto M, Baldini M, Dei CA, et al. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a mul-ticenter, randomized, double-blind study. Thromb Res 2007; 119:85-91.
37. Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause 2005;12:444-452.
38. Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 2004;147: 783-789.
39. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-857.
40. Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 2006;97:520-527.
41. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 95;38:199-210.
42. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) research group. JAMA 1998;280:605-613.
43. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
44. Goldstein SR, Neven P, Zhou L, Taylor YL, Ciaccia AV, Plouffe L. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 2001;98:91-96.
45. Neven P, Goldstein SR, Ciaccia AV, Zhou L, Silfen SL, Muram D. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol 2002;85:388-390.
46. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-73.
47. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344: 1207-1213.
48. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005;162:683-690.
49. Utian WH, Janata JW, Barbier S, et al. Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) scale. Menopause 2004; 11:275-280.
50. Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000;96:359-365.
51. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-2751.